沙库巴曲缬沙坦防治肿瘤治疗相关心功能不全的效果分析
Efficacy analysis of sacubitril/valsartan in the prevention and treatment of cardiac dys-function related to tumor therapy
林艺婷 1韩晴 1郭小博 2张红梅3
作者信息
- 1. 空军军医大学基础医学院学员四大队(西安市 710032)
- 2. 空军军医大学基础医学院学员六大队
- 3. 空军军医大学西京医院肿瘤科
- 折叠
摘要
目的:探讨沙库巴曲缬沙坦治疗肿瘤治疗相关心功能不全(cancer therapy-related cardiac dysfunction,CTRCD)的疗效.方法:汇总分析自建库至 2023年 3月发表于Pubmed、Web of Science、Cochrane Library、Medline、Embase五大数据库的沙库巴曲缬沙坦治疗CTRCD的所有文献,归纳总结用药时机、剂量、药物疗效等;梳理总结其预防CTRCD的临床研究.结果:使用沙库巴曲缬沙坦治疗CTRCD 3～12个月后,肿瘤患者NYHA心功能从Ⅱ～Ⅳ级改善为Ⅰ～Ⅱ级,LVEF上升幅度为 3.0%～37.0%,NT-proBNP下降幅度为 280.0～65 498.0 pg/mL.结论:沙库巴曲缬沙坦治疗CTRCD有效,在改善患者LVEF、GLS等指标方面具有较好的临床应用价值,使肿瘤患者抗肿瘤治疗得以继续、生存期得以延长.
Abstract
Objective:To investigate the efficacy of sacubitril/valsartan in the treatment of cancer therapy-related cardiac dysfunction(CTRCD).Methods:A comprehensive analysis of all the literature on sacubitril/valsartan therapy for CTRCD published in Pubmed,Web of Science,Cochrane Library,Medline,and Embase from the inception of the database up to March 2023 was conducted,summarizing the tim-ing of drug administration,dosage,and efficacy,and further systematically summarizing the clinical studies on the use of the drug for the prevention of CTRCD.Results:After 3-12 months of treatment with sacubitril/valsartan for CTRCD,NYHA in cancer patients improved from grade Ⅱ-Ⅳ to grade Ⅰ-Ⅱ,LVEF increased by 3.0%to 37.0%,and NT-proBNP decreased by 280.0-65 498.0 pg/mL.Conclusions:The sacu-bitril/valsartan demonstrates efficacy in managing CTRCD and holds significant clinical utility in enhancing LVEF,GLS,and other patient indic-ators,thereby enabling the continuation of anti-tumor therapy and prolonging survival for cancer patients.
关键词
沙库巴曲缬沙坦/肿瘤治疗相关心功能不全/心力衰竭/肿瘤心脏病学Key words
sacubitril/valsartan/cancer therapy-related cardiac dysfunction(CTRCD)/heart failure/tumor cardiology引用本文复制引用
基金项目
陕西省自然科学基础研究计划(2021ZJ-35)
空军军医大学临床研究课题(2021LC2212)
西京医院临床研究专项(XJZT24LZ15)
出版年
2024
NETL
NSTL
万方数据